Journal of Gastroenterology and Hepatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 3, 2024
Abstract
There
is
increasing
evidence
that
cannabidiol
(CBD)
use
associated
with
clinically
significant
liver
enzyme
(LE)
elevations
and
drug‐induced
injury
(DILI).
The
proportion
of
LE
DILI
events
reported
in
the
literature
meet
Council
for
International
Organizations
Medical
Sciences'
(CIOMS)
classification
a
common
adverse
drug
reaction.
However,
these
potential
are
unknown
to
many
clinicians
may
be
overlooked.
CBD
both
medical
non‐medical
necessitates
clear
direction
diagnosis
management
CBD‐associated
hepatotoxicity.
To
our
knowledge,
no
such
clinical
guidance
currently
exists.
For
people
presenting
elevated
LEs,
should
screened
considered
differential
diagnosis.
This
narrative
review
will
provide
prevention,
detection,
CBD‐related
Acta Physiologica,
Год журнала:
2024,
Номер
240(12)
Опубликована: Окт. 24, 2024
Cannabinoids
are
a
class
of
drugs
derived
from
the
Cannabis
plant
that
widely
used
for
treatment
various
medical
conditions
and
recreational
use.
Common
examples
include
Δ
Biomolecules,
Год журнала:
2023,
Номер
13(10), С. 1446 - 1446
Опубликована: Сен. 26, 2023
The
use
of
cannabinoids
(substances
contained
specifically
in
hemp
plants)
for
therapeutic
purposes
has
received
increased
attention
recent
years.
Presently,
is
paid
to
two
main
cannabinoids:
delta-9-tetrahydrocannabinol
(THC)
and
cannabidiol
(CBD).
With
respect
the
psychotropic
effects
dependence
potential
THC
(though
it
very
mild),
its
associated
with
certain
restrictions,
thus
properties
CBD
are
frequently
emphasized
because
there
no
limitations
risk
dependence.
Therefore,
this
review
covers
pharmacodynamic
pharmacokinetic
features
(including
characteristics
endocannabinoidome)
possible
beneficial
on
selected
diseases
clinical
practice.
A
substantial
part
text
deals
aging,
including
Alzheimer’s
disease
related
underlying
mechanisms.
Journal of Gastroenterology and Hepatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 3, 2024
Abstract
There
is
increasing
evidence
that
cannabidiol
(CBD)
use
associated
with
clinically
significant
liver
enzyme
(LE)
elevations
and
drug‐induced
injury
(DILI).
The
proportion
of
LE
DILI
events
reported
in
the
literature
meet
Council
for
International
Organizations
Medical
Sciences'
(CIOMS)
classification
a
common
adverse
drug
reaction.
However,
these
potential
are
unknown
to
many
clinicians
may
be
overlooked.
CBD
both
medical
non‐medical
necessitates
clear
direction
diagnosis
management
CBD‐associated
hepatotoxicity.
To
our
knowledge,
no
such
clinical
guidance
currently
exists.
For
people
presenting
elevated
LEs,
should
screened
considered
differential
diagnosis.
This
narrative
review
will
provide
prevention,
detection,
CBD‐related
